

matography of this on activity-3 neutral alumina using 20% ether/hexane elution gave 40 mg (93%) of the ketone **5** as a clear oil.

B. To 70 mg (0.15 mmol) of the silyl enol ether **15** in 0.5 mL of THF at 0 °C was added 0.17 mL of the hexylborane (0.5 M solution in THF, 0.17 mmol), and the mixture was warmed to 20 °C for 18 h. Addition of 0.2 mL of 3 N aqueous sodium hydroxide solution and 0.2 mL of 30% hydrogen peroxide solution at 0 °C, stirring of the two-phase solution for 30 min, extraction of this mixture with ether, washing of the organic layer with brine, drying of it over sodium sulfate, and concentration gave a crude oil. This was purified by chromatography on activity-3 neutral alumina with 20% ether/hexane to give 50 mg (76%) of the ketone **5** as a clear oil.

¹H NMR (200 MHz, CDCl₃) δ 3.2-3.7 (5 H, br m), 1.5-2.5 (9 H, br m), 0.90 (9 H, s), 0.89 (9 H, s), 0.10 (6 H, s), 0.07 (6 H, s); IR (neat) 3050-3600, 2750-3000, 1740, 1480, 1260, 1100, 920, 850, 790, 740 cm⁻¹; MS (70 eV), *m/e* (% intensity) 371 (M⁺ - *tert*-Bu, 0.7), 353 (M⁺ - *t*-Bu

- H₂O, 1.9), 271 (3.6), 239 (M⁺ - TBSOH - *i*-Bu, 5.3), 223 (M⁺ - TBSOH - isobutylene - OH, 7.0), 131 (17.7), 91 (10.2), 89 (17.7), 75 (OSiMe₂H⁺, 100); high-resolution MS (70 eV), *m/e* 371.2087, calcd for C₁₈H₃₅O₄Si₂ 371.2074, 353.1983, calcd for C₁₈H₃₃O₃Si₂ 353.1969, 223.1157, calcd for C₁₂H₁₉O₂Si 223.1155.

Acknowledgment. We thank the National Institutes of Health (GM-31349) for support of this work and Dr. James Snyder of Merck, Sharp and Dohme Co. for the force-field calculations.

Registry No. **1**, 50-55-5; **5**, 92420-94-5; **6**, 64145-56-8; **7a**, 92420-95-6; **7b**, 92420-96-7; **8a**, 92420-97-8; **8b**, 92420-98-9; **9**, 92420-99-0; **10**, 92421-00-6; **11**, 92421-01-7; **13**, 92421-02-8; **14**, 92421-03-9; **Δ⁵-15**, 92421-04-0; **Δ⁵-15**, 92421-05-1; propargyl alcohol, 107-19-7; propargyl benzyl ether, 4039-82-1; trimethylsilyl chloride, 75-77-4; *tert*-butyldimethylsilyl chloride, 18162-48-6.

Communications to the Editor

3-Alkoxy-7-amino-4-chloroisocoumarins: A New Class of Suicide Substrates for Serine Proteases

J. Wade Harper and James C. Powers*

School of Chemistry
Georgia Institute of Technology
Atlanta, Georgia 30332

Received July 5, 1984

Human leukocyte elastase (HLE) is a serine protease involved in a number of disease states including pulmonary emphysema. As such, there is considerable interest in the development of therapeutically useful HLE inhibitors. Previously, a number of heterocyclic structures have been shown to be suicide substrates of serine proteases.¹⁻³ Here we report that 3-alkoxy-7-amino-4-chloroisocoumarins are suicide substrates of HLE, porcine pancreatic elastase (PPE), and bovine chymotrypsin A_α (ChT).

Incubation of the 7-amino-4-chloroisocoumarins⁴ **2** and **6**, the 7-nitro-4-chloroisocoumarins⁴ **1** and **5**, 7-amino-3-methoxyisocoumarin⁵ **3**, and 4-chloro-3-ethoxyisocoumarin⁶ (**4**) with HLE and PPE resulted in a time-dependent loss of enzymatic activity (Table I). ChT was also inactivated by **2** and **6** with *k*_{obsd}/[I] values of 108 M⁻¹ s⁻¹ ([I] = 0.1 mM) and 270 M⁻¹ s⁻¹ ([I] = 0.02 mM), respectively. While >99% inactivation was observed with 7-amino-4-chloroisocoumarins **2** and **6**, a maximum of 70-95% inactivation was observed with **1** and **3-5** under the conditions utilized. Inactivation of PPE (1.7 μM) by the 7-amino-4-chloroisocoumarin **2** (16 μM) in the presence of the reversible competitive inhibitor CF₃CO-Lys-Ala-4-methylanilide⁷ (15 μM) resulted in a decrease in the inactivation rate (*k*_{obsd}/[I] = 76 M⁻¹

Table I. Inactivation of Serine Proteases by Substituted 3-Alkoxyisocoumarins^a

enzyme		inhibitor concentration, μM	<i>k</i> _{obsd} /[I], M ⁻¹ s ⁻¹	<i>k</i> _{reactivation} , s ⁻¹
HL elastase	1	15	>2600 ^b	0.5 × 10 ⁻³
	2	5	10000	0 ^c
	3	112	200	
	4	0.6	43000 ^d	0.2 × 10 ⁻³ ^e
	5	34	>2800 ^b	0.33 × 10 ⁻³
PP elastase	6	4.4	9500	0 ^c
	1	40	>600 ^b	0.5 × 10 ⁻³
	2	16	1000	0 ^c
	3	91	18	
	4	37	1400	0.16 × 10 ⁻³
	5	30	>1300 ^b	1.3 × 10 ⁻³
	6	19	700	0 ^c

^a Unless otherwise noted, enzyme (0.4-2.0 μM) was incubated with inhibitor in 0.25-0.6 mL of 0.1 M Hepes, 0.5 M NaCl, pH 7.5, 8-12% Me₂SO at 25 °C. Aliquots (10-50 μL) were withdrawn at various times and the residual enzymatic activity measured as previously described.³ The *k*_{obsd} values were calculated from plots of ln *v*/*v*₀ vs. time with *r* > 0.99. ^b Inactivation was extremely rapid and the *k*_{obsd}/[I] values are based on residual enzymatic activity at 0.25 min. ^c Less than 0.5% activity regained after standing 100 h at 25 °C. Controls retained >90% enzymatic activity over this time period. ^d Inactivation rate measured using the progress curve method¹⁰ with 0.171 mM MeO-Suc-Ala-Ala-Pro-Val-4-nitroanilide and 8 nM HLE. ^e [I] = 0.013 mM.

s⁻¹), indicating that **2** is active-site directed.

Loss of the isocoumarin ring chromophore of 7-amino-4-chloro-3-ethoxyisocoumarin (**6**) (0.030 mM, ε₃₈₅ = 3330 M⁻¹ cm⁻¹; spontaneous hydrolysis, 5.9 × 10⁻⁵ s⁻¹) occurred concurrently with inactivation of PPE (6.4 μM, *k*_{obsd}/[I] = 940 M⁻¹ s⁻¹) and ChT (12.6 μM, *k*_{obsd}/[I] = 200 M⁻¹ s⁻¹). A reaction stoichiometry of 1.03 ± 0.07 and 1.31 ± 0.03 equiv of **6** with PPE and ChT, respectively, was calculated from the absorbance change (385 nm). The inactivated enzymes showed no new bands in the UV-visible spectrum before or after dialysis (0.1 M phosphate pH 6.8 buffer, 48 h, 4 °C). The reaction of 4-chloro-3-ethoxyisocoumarin (**4**) (0.066 mM) with ChT (0.050 mM) was monitored by the absorbance decrease at 350 nm (ε = 2920 M⁻¹ cm⁻¹) and 0.97 equiv of **4** are required for total (>99%) inactivation. PPE (7 μM) hydrolyzed 7-amino-3-methoxyisocoumarin (**3**) (0.054 mM, ε₃₈₅ = 4300 M⁻¹ cm⁻¹; spontaneous hydrolysis, 3 × 10⁻⁵ s⁻¹) with a pre-steady-state rate constant of 0.75 × 10⁻³ s⁻¹ (burst = 0.66 equiv) and a steady-state rate constant of 0.084 × 10⁻³ s⁻¹.

The reaction of PPE (8.9 μM) with 7-amino-4-chloro-3-methoxyisocoumarin (**2**) (0.031 mM, 0.1 M phosphate buffer,

(1) Westkaemper, R. B.; Abeles, R. H. *Biochemistry* **1983**, *22*, 3256-3264.

(2) Vilkas, M. In "Enzyme-Activated Irreversible Inhibitors"; Seiler, N., Jung, M. J., Koch-Weser, J., Eds.; Elsevier/North Holland Biochemical Press: New York, 1978; pp 323-335.

(3) Harper, J. W.; Hemmi, K.; Powers, J. C. *J. Am. Chem. Soc.*, **1983**, *105*, 6518-6520.

(4) Choksey, I.; Usgaonkar, R. N. *Indian J. Chem. Sect. B* **1976**, *14B*, 596-598.

(5) 7-Amino-3-methoxyisocoumarin (**3**) was prepared by catalytic hydrogenation of 3-methoxy-7-nitroisocoumarin (500 mg) using Pd-C in MeOH for 45 min at 25 °C: 250 mg from MeOH/isopropyl ether, mp 160-161 °C dec. The 3-methoxy-7-nitroisocoumarin was prepared by treating methyl (4-nitro-2-carboxylphenyl)acetate (2.0 g) with (CF₃CO)₂O (1.4 mL) in CH₂Cl₂ at 25 °C for 16 h: 1.8 g from methylene chloride/petroleum ether, mp 148-150 °C dec. Satisfactory NMR, IR, UV, mass spectra, and elemental analysis were obtained for all compounds.

(6) Tirodkar, R. B.; Usgaonkar, R. N. *Indian J. Chem.* **1969**, *7*, 1114-1116.

(7) Renaud, A.; Lestienne, P.; Hughes, D. L.; Bieth, J. G.; Dimicoli, J. L. *J. Biol. Chem.* **1983**, *258*, 8312-8316.




Figure 1. Proposed pathway for inactivation of serine proteases by substituted 3-alkoxyisocoumarins.

pH 6.8, 10% Me₂SO) was also monitored by the decrease in fluorescence emission at 510 nm ($\epsilon_{\text{ex}} = 400$ nm), and the rate of ring opening ($18 \times 10^{-3} \text{ s}^{-1}$) was identical with the inactivation rate ($17 \times 10^{-3} \text{ s}^{-1}$) under these conditions. The inactivation stoichiometry (1.06 ± 0.02) was similar to that determined spectrophotometrically. No new emission bands ($\epsilon_{\text{ex}} = 400$ nm) were observed in the fluorescence spectra of inactivated PPE (8.9 μM) after dialysis against phosphate buffer (pH 6.8) for 24 h at 4 °C. Inactivation of ChT (0.27 mM) by **6** (0.33 mM) resulted in <1% release of EtOH.⁸

HLE and PPE inactivated by the 7-amino-4-chloroisocoumarins **2** and **6** regained <0.5% enzymatic activity after standing for 100 h, while these enzymes inactivated by the 7-nitro derivatives **1** and **5** and the 4-chloro-3-ethoxyisocoumarin (**4**) regained >85% activity ($t_{1/2} < 72$ min) upon standing at 25 °C (Table I). In addition, HLE and PPE inactivated by **6** regained <0.5% enzymatic activity after dialysis for 48 h (0.1 M phosphate pH 6.8 buffer, 4 °C) and upon further standing for 48 h at 25 °C, which is evidence for irreversible inactivation. Addition of buffered hydroxylamine (0.46 M) to HLE and PPE inactivated by **6** (0.016 mM) resulted in 34–42% reactivation ($t_{1/2} = 5.7$ –7.2 h), while addition of buffered hydroxylamine (0.26 mM) to these enzymes inactivated by 7-amino-3-methoxyisocoumarin (**3**) (0.09–0.11 mM) resulted in rapid and complete reactivation ($t_{1/2} = 12$ and 9.6 min, respectively).

These results are consistent with Figure 1 where the 3-alkoxy-7-amino-4-chloroisocoumarins **2** and **6** react with the active-site serine of serine proteases to give the acyl enzyme **7** which decomposes to the acyl-*p*-quinonemethide imine **8**. An irreversibly inactivated enzyme could then result by reaction of the acyl-*p*-quinonemethide imine **8** with an active-site nucleophile.⁹ The requirement of both the 7-amino and 4-chloro substituents for irreversible inactivation is demonstrated by the finding that the 7-nitro-4-chloroisocoumarins **1** and **5**, 4-chloroisocoumarin **4**, and 7-aminoisocoumarin (**3**) react to give **7** but reactivate rapidly either upon standing or upon addition of hydroxylamine. The 3-alkoxy-7-amino-4-chloroisocoumarins **2** and **6** are some of the most potent HLE inactivators yet reported, represent a new class of

(8) EtOH release measured upon dilution (2 \times) of inactivated enzyme into liver alcohol dehydrogenase (1 μM) and NAD⁺ (1.5 mM) in 0.1 M phosphate pH 7.8 buffer. Alcohol dehydrogenase was measured by monitoring the increase in absorbance of NADH at 340 nm ($\epsilon = 6220 \text{ M}^{-1} \text{ cm}^{-1}$) and <2 μM ethanol could have been detected.

(9) Several *p*-aminobenzyl halides react rapidly with nucleophiles through a *p*-quinonemethide imine intermediate: Wakselman, M.; Dome, M. *Bull. Soc. Chim. Fr.* **1975**, 571–575. Dome, M.; Wakselman, M. *Bull. Soc. Chim. Fr.* **1975**, 576–582.

(10) Tian, W. X.; Tsou, C. L. *Biochemistry* **1982**, *21*, 1028–1032.

suicide substrates for serine proteases, and may be useful in the prevention of proteolysis *in vitro* and *in vivo*. Studies leading to further proof of the proposed mechanism and extension to other serine proteases are now in progress.

Acknowledgment. This work was supported by grants from the National Institutes of Health (HL 29307) and from the Council for Tobacco Research.

The Kharasch Reagent. Regioselective Generation of Dienol Ethers from Enones


Marie E. Krafft* and Robert A. Holton*

Department of Chemistry
Virginia Polytechnic Institute and State University
Blacksburg, Virginia 24061

Received June 29, 1984

After a hiatus of over 40 years, we have uncovered the identity of the Kharasch reagent.¹ Stoichiometric use of this reagent now makes possible, for the first time, the regioselective preparation of "thermodynamic" trimethylsilyl dienol ethers from cyclic enones.

Deprotonation of a cyclic enone (e.g., **1**) can potentially give three regioisomeric dienolates: the cross-conjugated ("kinetic") isomer **1k**, the through-conjugated ("thermodynamic") endocyclic isomer **1nt**, and through-conjugated ("thermodynamic") exocyclic isomer **1xt**. The synthetic utility of dienolates **1k**, **1nt**, and **1xt**



has been recognized for some time.^{2–4} However, exploitation of this utility requires methods for the regiospecific preparation of each of the three possible dienolates. Unfortunately, prior to this work only enolates of type **1k** have been generally accessible from the corresponding enone (LDA/THF/−78 °C).^{2c,5,6}

One of the rare examples of formation of a through-conjugated dienolate from the corresponding enone was reported by Kharasch.¹ In a modified version of this reaction, treatment of **2** with

(1) Kharasch, M. S.; Tawney, P. O. *J. Am. Chem. Soc.* **1941**, *63*, 2308; **1945**, *67*, 128. For subsequent synthetic uses, see: Meinwald, J.; Hendry, L. *J. Org. Chem.* **1971**, *36*, 1446 and references cited therein.

(2) For reviews of the use of enol ethers in synthesis, see: (a) Effenberger, F. *Angew. Chem., Int. Ed. Engl.* **1969**, *8*, 295. (b) Rasmussen, J. K. *Synthesis* **1977**, 91. (c) D'Angelo, J. *Tetrahedron* **1976**, *32*, 2979.

(3) Acylation: (a) Burn, D.; Cooley, C.; Davies, M. T.; Hiscock, A. K.; Kirk, D. N.; Petrow, V.; Williamson, D. M. *Tetrahedron* **1965**, *21*, 569. (b) Gorodetsky, M.; Levy, E.; Youssefyeh, R. D.; Mazur, Y. *Ibid.* **1966**, *22*, 2039.

(4) Lewis acid catalyzed aldol-type processes: (a) Danishefsky, S.; Prisybylla, M.; Lipisko, B. *Tetrahedron Lett.* **1980**, 805. (b) Fleming, I.; Lee, T. V. *Ibid.* **1981**, 705. (c) Fleming, I.; Goldhill, J.; Paterson, I. *Ibid.* **1979**, 3205, 3209. (d) Danishefsky, S.; Guingant, A.; Prisybylla, M. *Ibid.* **1980**, 2033. (e) For a recent review, see: Fleming, I. *Chimia* **1980**, *34*, 265.

(5) General preparation of "kinetic" dienolates **1k**: (a) Lee, R. A.; McAndrews, C.; Patel, K. M.; Reusch, W. *Tetrahedron Lett.* **1973**, 965. (b) Stork, G.; Danheiser, R. *J. Org. Chem.* **1973**, *38*, 1775.

(6) Specific instances of preparation of "thermodynamic" dienolates **1nt** and **1xt** or mixtures of these: (a) Conia, J. M. *Tetrahedron Lett.* **1964**, 2791. (b) Conia, J. M.; Sandre-Le Craz *Ibid.* **1962**, 505 and references cited therein. (c) Wharton, P. S. *J. Org. Chem.* **1968**, *33*, 4255. (d) House, H. O.; Czuba, L. J.; Gall, M.; Olmstead, H. D. *Ibid.* **1969**, *34*, 2324. (e) Rubottom, G. M.; Gruber, J. M. *Ibid.* **1977**, *42*, 1051. (f) Leffingwell, J. C. *Tetrahedron Lett.* **1970**, 1653. (g) Treatment of **2** with KO-*t*-Bu/THF/Me₃SiCl/Et₃N led to a 3:7 mixture of **2nt/2xt** (X = Me₃Si). (h) Some through-conjugated endocyclic dienol ethers are available via reduction–rearrangement of appropriate aromatic substrates.^{2a,b,4c}